4 October 2023 - Even in the final report, many questions about the treatment of relapsing-remitting multiple sclerosis remain unanswered because there is a lack of clinical trial data: benefits can therefore only be seen in three out of ten active substances examined.

The Federal Joint Committee commissioned the IQWiG to evaluate a total of ten active ingredients for the treatment of multiple sclerosis: the immunomodulators cladribine, dimethyl fumarate, ozanimod, ponesimod, teriflunomide, fingolimod and the monoclonal antibodies alemtuzumab, natalizumab, ocrelizumab, ofatumumab are said to have a beneficial effect on the immune system of those affected with relapsing-remitting multiple sclerosis, the most common form of multiple sclerosis.

Read IQWiG press release [German]